These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 21883151

  • 1. Pharmacological characterization of a small-molecule agonist for the chemokine receptor CXCR3.
    Scholten DJ, Canals M, Wijtmans M, de Munnik S, Nguyen P, Verzijl D, de Esch IJ, Vischer HF, Smit MJ, Leurs R.
    Br J Pharmacol; 2012 Jun; 166(3):898-911. PubMed ID: 21883151
    [Abstract] [Full Text] [Related]

  • 2. Small molecule chemokine mimetics suggest a molecular basis for the observation that CXCL10 and CXCL11 are allosteric ligands of CXCR3.
    Nedjai B, Li H, Stroke IL, Wise EL, Webb ML, Merritt JR, Henderson I, Klon AE, Cole AG, Horuk R, Vaidehi N, Pease JE.
    Br J Pharmacol; 2012 Jun; 166(3):912-23. PubMed ID: 21895630
    [Abstract] [Full Text] [Related]

  • 3. Label-free impedance responses of endogenous and synthetic chemokine receptor CXCR3 agonists correlate with Gi-protein pathway activation.
    Watts AO, Scholten DJ, Heitman LH, Vischer HF, Leurs R.
    Biochem Biophys Res Commun; 2012 Mar 09; 419(2):412-8. PubMed ID: 22349504
    [Abstract] [Full Text] [Related]

  • 4. Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function.
    Colvin RA, Campanella GS, Sun J, Luster AD.
    J Biol Chem; 2004 Jul 16; 279(29):30219-27. PubMed ID: 15150261
    [Abstract] [Full Text] [Related]

  • 5. Identification and profiling of CXCR3-CXCR4 chemokine receptor heteromer complexes.
    Watts AO, van Lipzig MM, Jaeger WC, Seeber RM, van Zwam M, Vinet J, van der Lee MM, Siderius M, Zaman GJ, Boddeke HW, Smit MJ, Pfleger KD, Leurs R, Vischer HF.
    Br J Pharmacol; 2013 Apr 16; 168(7):1662-74. PubMed ID: 23170857
    [Abstract] [Full Text] [Related]

  • 6. The yin and yang of chemokine receptor activation.
    O'Boyle G.
    Br J Pharmacol; 2012 Jun 16; 166(3):895-7. PubMed ID: 22035113
    [Abstract] [Full Text] [Related]

  • 7. Cross reactivity of three T cell attracting murine chemokines stimulating the CXC chemokine receptor CXCR3 and their induction in cultured cells and during allograft rejection.
    Meyer M, Hensbergen PJ, van der Raaij-Helmer EM, Brandacher G, Margreiter R, Heufler C, Koch F, Narumi S, Werner ER, Colvin R, Luster AD, Tensen CP, Werner-Felmayer G.
    Eur J Immunol; 2001 Aug 16; 31(8):2521-7. PubMed ID: 11500837
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pharmacological characterization of [3H]VUF11211, a novel radiolabeled small-molecule inverse agonist for the chemokine receptor CXCR3.
    Scholten DJ, Wijtmans M, van Senten JR, Custers H, Stunnenberg A, de Esch IJ, Smit MJ, Leurs R.
    Mol Pharmacol; 2015 Apr 16; 87(4):639-48. PubMed ID: 25576486
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. CXCR3 Ligands in Cancer and Autoimmunity, Chemoattraction of Effector T Cells, and Beyond.
    Karin N.
    Front Immunol; 2020 Apr 16; 11():976. PubMed ID: 32547545
    [Abstract] [Full Text] [Related]

  • 13. Interleukin-27 and IFNγ regulate the expression of CXCL9, CXCL10, and CXCL11 in hepatitis.
    Basset L, Chevalier S, Danger Y, Arshad MI, Piquet-Pellorce C, Gascan H, Samson M.
    J Mol Med (Berl); 2015 Dec 16; 93(12):1355-67. PubMed ID: 26199110
    [Abstract] [Full Text] [Related]

  • 14. Pharmacological characterization of CXC chemokine receptor 3 ligands and a small molecule antagonist.
    Heise CE, Pahuja A, Hudson SC, Mistry MS, Putnam AL, Gross MM, Gottlieb PA, Wade WS, Kiankarimi M, Schwarz D, Crowe P, Zlotnik A, Alleva DG.
    J Pharmacol Exp Ther; 2005 Jun 16; 313(3):1263-71. PubMed ID: 15761110
    [Abstract] [Full Text] [Related]

  • 15. Biased agonists of the chemokine receptor CXCR3 differentially control chemotaxis and inflammation.
    Smith JS, Nicholson LT, Suwanpradid J, Glenn RA, Knape NM, Alagesan P, Gundry JN, Wehrman TS, Atwater AR, Gunn MD, MacLeod AS, Rajagopal S.
    Sci Signal; 2018 Nov 06; 11(555):. PubMed ID: 30401786
    [Abstract] [Full Text] [Related]

  • 16. Noncompetitive antagonism and inverse agonism as mechanism of action of nonpeptidergic antagonists at primate and rodent CXCR3 chemokine receptors.
    Verzijl D, Storelli S, Scholten DJ, Bosch L, Reinhart TA, Streblow DN, Tensen CP, Fitzsimons CP, Zaman GJ, Pease JE, de Esch IJ, Smit MJ, Leurs R.
    J Pharmacol Exp Ther; 2008 May 06; 325(2):544-55. PubMed ID: 18270317
    [Abstract] [Full Text] [Related]

  • 17. Analysis of the pharmacokinetic/pharmacodynamic relationship of a small molecule CXCR3 antagonist, NBI-74330, using a murine CXCR3 internalization assay.
    Jopling LA, Watt GF, Fisher S, Birch H, Coggon S, Christie MI.
    Br J Pharmacol; 2007 Dec 06; 152(8):1260-71. PubMed ID: 17982480
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. CXC Chemokine Receptor 3 Alternative Splice Variants Selectively Activate Different Signaling Pathways.
    Berchiche YA, Sakmar TP.
    Mol Pharmacol; 2016 Oct 06; 90(4):483-95. PubMed ID: 27512119
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.